We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Experimental Drug Stops Cancer Growth by Activating Integrin-Based Apoptosis

By LabMedica International staff writers
Posted on 13 Jun 2016
An experimental drug blocks tumor growth by binding to a novel site on the surface receptor integrin alphavbeta3, which activates the apoptotic factor caspase 8 and leads to the death of the cancer cells.

Expression of the integrin alphavbeta3 is altered in various diseases and has been proposed as a drug target. More...
Integrins are transmembrane receptors that mediate the attachment between a cell and the tissues that surround it, such as other cells or the extracellular matrix (ECM). Integrin molecules do not adhere to their appropriate ligands until cells are activated by chemotactic agents or other stimuli. Only then do the integrins undergo the conformational change necessary to confer high binding affinity for the endothelial adhesion molecules.

Investigators at Georgia State University (Atlanta, USA) used a rational design approach to develop a therapeutic protein, which they called ProAgio. This protein was shown to bind to integrin alphavbeta3 outside the classical ligand-binding site.

Results published in the May 31, 2016, online edition of the journal Nature Communications revealed that ProAgio induced apoptosis of integrin alphavbeta3-expressing cells by recruiting and activating caspase 8 to the cytoplasmic domain of integrin alphavbeta3. Caspases (cysteine-aspartic proteases) are a family of protease enzymes playing essential roles in programmed cell death (including apoptosis, pyroptosis, and necroptosis) and inflammation. Activation of caspases ensures that the cellular components are degraded in a controlled manner, carrying out cell death with minimal effect to surrounding tissues.

ProAgio was also found to express potent anti-angiogenic activity and strongly inhibited growth of tumor xenografts in mice, but did not affect the established vasculature. Toxicity analyses demonstrated that ProAgio was not toxic to mice.

"This integrin pair, alphavbeta3, is not expressed in high levels in normal tissue," said senior author Dr. Zhi-Ren Liu, professor of biology at Georgia State University. "In most cases, it is associated with a number of different pathological conditions. Therefore, it constitutes a very good target for multiple disease treatment. We took a unique angle. We designed a protein that binds to a different site. Once the protein binds to the site, it directly triggers cell death. When we are able to kill pathological cells, then we are able to kill the disease."

Related Links:
Georgia State University


New
Gold Member
Blood Gas Analyzer
Stat Profile pHOx
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Staining System
RAL DIFF-QUIK
New
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.